Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours
Cancer Medicine · 2025
DOI: 10.1002/cam4.70910 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Martina Čarnogurská und 10 weiteren Autor:innen. Beteiligte Einrichtung: RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (Originalsprache)
Background
Emerging evidence suggests that tumour morphological heterogeneity may influence mutational profiles relevant to therapy response. In this pilot study, we aimed to assess whether mutations identified within specific morphological patterns or at the invasion front correlate with shorter time to progression after anti‐EGFR therapy, as compared to whole‐tissue analysis.
Methods
We investigated genetic mutations in 142 samples from primary tumours of 39 KRAS wild‐type metastatic colorectal cancer (CRC) patients receiving anti‐EGFR therapy. Deep next‐generation sequencing was performed on whole‐tumour sections and six morphology‐defined tumour regions.
Results
Mutations in genes linked to anti‐EGFR therapy response ( KRAS , BRAF , NRAS , PTEN and PI3KCA ) were found uniquely in the non‐responder group, with substantial variability across morphological sub‐regions. BRAF mutations were aligned with serrated and mucinous morphologies, while KRAS mutations (p.Lys147Glu and p.Ala146Thr) were associated with mucinous and desmoplastic morphologies. In all cases, the cumulative mutational profile from sub‐regions provided more details than that of the whole‐tumour profile.
Conclusion
Our findings highlight that comprehensive analysis, considering morphological heterogeneity, is crucial for personalised CRC treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
- Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- Masaryk Memorial Cancer Institute, Brno, Czech Republic.
ORCID-Profile: Martina Čarnogurská, Ondrej Slabý
Förderung
- Horizon 2020 Framework Programme
- Ministerstvo Zdravotnictví Ceské Republiky
Zitieren
APA
Čarnogurská, M., Vasylieva, V. S., Macháčková, T., Boudná, M., Pifková, L., Orlíčková, J., Ivkovic, T. C., Slabý, O., Bencsiková, B., Popovici, V., & Budinská, E. (2025). Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours. Cancer Medicine. https://doi.org/10.1002/cam4.70910
Vancouver
Čarnogurská M, Vasylieva VS, Macháčková T, Boudná M, Pifková L, Orlíčková J, et al. Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours. Cancer Medicine. 2025. doi:10.1002/cam4.70910
BibTeX
@article{arnogursk2025,
author = {Čarnogurská, Martina and Vasylieva, Valeriia Serhiivna and Macháčková, Táňa and Boudná, Marie and Pifková, Lucie and Orlíčková, Jana and Ivkovic, Tina Catela and Slabý, Ondrej and Bencsiková, Beatrix and Popovici, Vlad and Budinská, Eva},
title = {Search for Mutations Connected With Non‐Response to Anti‐ EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70910}
}
EUVIMED